European Union vaccine research—An overview

• Published in: Vaccine Vol. 29; no. 39; pp. 6723 - 6727
• Main Authors: Sautter, Jürgen, Olesen, Ole F., Bray, Jeremy, Draghia-Akli, Ruxandra
• Format: Journal Article Conference Proceeding
• Language: English
• Published: Kidlington Elsevier Ltd 09.09.2011; Elsevier; Elsevier Limited
• Subjects: Acquired immune deficiency syndrome; AIDS; Allergy and Immunology; Animals; Applied microbiology; Biological and medical sciences; Biomedical Research - economics; Biomedical Research - organization & administration; Clinical Trials as Topic; Deoxyribonucleic acid; DNA; DNA vaccine; Europe; European Union; Fundamental and applied biological sciences. Psychology; guidelines; Humans; Immunization Programs - economics; Immunization Programs - organization & administration; industry; Innovations; International Cooperation; markets; Medical research; Microbiology; Pharmaceutical industry; Public Health; Public-Private Sector Partnerships - economics; Public-Private Sector Partnerships - organization & administration; recombinant vaccines; Research funding; Research Support as Topic - economics; Research Support as Topic - legislation & jurisprudence; Research Support as Topic - organization & administration; small and medium enterprises; stakeholders; Tuberculosis; vaccine development; Vaccines; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects); Vaccines, DNA - administration & dosage; Vaccines, DNA - economics; Europe; DNA vaccine; European Union; Research funding; Genetic vaccine
• ISSN: 0264-410X; 1873-2518; 1873-2518
• DOI: 10.1016/j.vaccine.2010.12.060

Recent developments in vaccine research provide new momentum for an important area in health innovation. Particularly interesting are novel DNA vaccine approaches, many of which are already under clinical investigation. The Framework Programmes of the European Union play an important role in supporting collaborative efforts in vaccine research to develop new and better vaccines and bring them to the market. With a timely strategic reorientation towards a sustainable investment in innovation, the current seventh Framework Programme will help to bring large industry and small and medium-sized enterprises (SME) on board and foster partnership between stakeholders. As the first human DNA vaccines progresses through the development pipeline, more and more questions revolve around licensing and regulation and appropriate guidelines are being developed.